Within 24 hours of receiving a prescribed dose of semaglutide, a weight loss medication, 31-year-old Karleigh McClain was hospitalized due to severe vomiting. After a telehealth consultation, she was instructed to inject 2.21 milligrams weekly, a dosage nearly nine times the typical first dose. Despite her concerns about the high dosage, a representative from the telehealth company confirmed it was correct. Following her hospitalization, McClain continues to experience lingering side effects, such as an elevated heart rate and vision problems. The rise of telehealth, especially since the COVID-19 pandemic, has led to increased prescriptions of GLP-1 medications like semaglutide, but also to reports of medication errors and adverse effects, raising concerns among healthcare professionals about the quality of care provided by some online medical services.
Why It Matters
Telehealth services have expanded significantly since 2020, making healthcare more accessible, particularly during the pandemic. However, the lack of stringent oversight and variability in state regulations can lead to prescription errors and inadequate patient care. Data shows that many patients receive prescriptions for GLP-1 medications without comprehensive evaluations, increasing the potential for serious health risks. The situation highlights the need for more robust guidelines and monitoring in telehealth practices, particularly concerning high-risk medications.
Want More Context? 🔎
